Xie W, Barwick JL, Downes M, Blumberg B, Simon CM, Nelson MC, Neuschwander-
Tetri BA, Brunt EM, Guzelian PS, Evans RM. Humanized xenobiotic response in
mice expressing nuclear receptor SXR. Nature 2000;406:435–439.
Xie W, Evans RM. Pharmaceutical use of mouse models humanized for the xenobiotic
receptor. Drug Discov Today 2002;7:509–515.
Yueh MF, Kawahara M, Raucy J. Cell-based high-throughput bioassays to assess
induction and inhibition of CYP1A enzymes. Toxicol In Vitro 2005a;19:275–287.
Yueh MF, Kawahara M, Raucy J. High volume bioassays to assess CYP3A4-mediated
drug interactions: induction and inhibition in a single cell line. Drug Metab Dispos
2005b;33:38–48.
Zhang ZY, Wong YN. Enzyme kinetics for clinically relevant CYP inhibition. Curr
Drug Metab 2005;6:241–257.
Zhao XJ, Jones DR, Wang YH, Grimm SW, Hall SD. Reversible and irreversible
inhibition of cyp3a enzymes by tamoxifen and metabolites. Xenobiotica 2002;32:
863–878.
Zhou J, Zhang J, Xie W. Xenobiotic nuclear receptor-mediated regulation of udp-
glucuronosyltransferases. Curr Drug Metab 2005;6:289–298.
Zhou S, Chan E, Pan SQ, Huang M, Lee EJ. Pharmacokinetic interactions of drugs
with St john’s wort. J Psychopharmacol 2004;18:262–276.
Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, McLeod HL.
Mechanism-based inhibition of cytochrome p450 3a4 by therapeutic drugs. Clin
Pharmacokinet 2005;44:279–304.
Zhu Z, Kim S, Chen T, Lin JH, Bell A, Bryson J, Dubaquie Y, Yan N, Yanchunas J,
Xie D, Stoffel R, Sinz M, Dickinson K. Correlation of high-throughput pregnane
x receptor (pxr) transactivation and binding assays. J Biomol Screen 2004;9:533–540.
136 METABOLISM-MEDIATED DRUG–DRUG INTERACTIONS